{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:41:17Z","timestamp":1771015277705,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T00:00:00Z","timestamp":1331596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>An international, Phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trial was conducted to assess two doses of ofatumumab, a human <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 monoclonal antibody, combined with cyclophosphamide (750\u00a0mg\/m<jats:sup>2<\/jats:sup>), doxorubicin (50\u00a0mg\/m<jats:sup>2<\/jats:sup>), prednisone (100\u00a0mg days 3\u20137) and vincristine (1\u00b74\u00a0mg\/m<jats:sup>2<\/jats:sup>) (O\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content>), as frontline treatment for follicular lymphoma (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>). 59 patients with previously untreated <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> were randomized to ofatumumab 500\u00a0mg (<jats:italic>n<\/jats:italic>\u00a0=\u00a029) or 1000\u00a0mg (<jats:italic>n<\/jats:italic>\u00a0=\u00a030) day 1, with <jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> on day 3 every 3\u00a0weeks for six cycles. Median duration of <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> was 0\u00b71\u00a0years for both dose groups; 34% and 38% of patients had high\u2010risk Follicular Lymphoma International Prognostic Index (<jats:styled-content style=\"fixed-case\">FLIPI<\/jats:styled-content>) scores in the 500\u2010 and 1000\u2010mg dose groups, respectively. Overall response rate was 90% for the 500\u2010mg group and 100% for the 1000\u2010mg group. 62% of patients achieved complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>)\/unconfirmed <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>u). 76% of patients with <jats:styled-content style=\"fixed-case\">FLIPI<\/jats:styled-content> score 3\u20135 attained <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>u. Longer follow\u2010up time is needed for analysis of survival end points. The most common Common Terminology Criteria grade 3\u20134 investigator\u2010reported adverse events were leucopenia (29%) and neutropenia (22%). No deaths have been reported. O\u2010<jats:styled-content style=\"fixed-case\">CHOP<\/jats:styled-content> was safe and efficacious in patients with previously untreated <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>, including high\u2010risk <jats:styled-content style=\"fixed-case\">FLIPI<\/jats:styled-content> groups. This trial was registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link> (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00494780).<\/jats:p>","DOI":"10.1111\/j.1365-2141.2012.09086.x","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T07:26:28Z","timestamp":1331623588000},"page":"438-445","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP<\/scp> in previously untreated follicular lymphoma"],"prefix":"10.1111","volume":"157","author":[{"given":"Myron S.","family":"Czuczman","sequence":"first","affiliation":[{"name":"Roswell Park Cancer Institute Buffalo NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin Mainz Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole V.","family":"Gadeberg","sequence":"additional","affiliation":[{"name":"Vejle Hospital Vejle Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars M.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Odense University Hospital Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Goldstein","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxanne C.","family":"Jewell","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Lin","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen","family":"Lisby","sequence":"additional","affiliation":[{"name":"Genmab A\/S Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Strange","sequence":"additional","affiliation":[{"name":"Genmab A\/S Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Windfeld","sequence":"additional","affiliation":[{"name":"Genmab A\/S Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the 409 Study Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-013367"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.07.003"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117671"},{"key":"e_1_2_9_6_1","first-page":"935","article-title":"Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab\u2010refractory follicular lymphoma","volume":"114","author":"Hagenbeek A.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900632"},{"key":"e_1_2_9_12_1","first-page":"405","article-title":"Bendamustine plus rituximab is superior in respect of progression\u2010free survival and CR rate when compared to CHOP plus rituximab as first\u2010line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"114","author":"Rummel M.J.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_13_1","first-page":"856","article-title":"Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas \u2010 Final Results of the Randomized Phase III Study NHL 2\u20102003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)","volume":"116","author":"Rummel M.J.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_2_9_15_1","first-page":"1788","article-title":"Updated results of the PRIMA study confirms the benefit of 2\u2010years rituximab maintenance in follicular lymphoma patients responding to immunochemotherapy","volume":"116","author":"Salles G.A.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"e_1_2_9_19_1","first-page":"855","article-title":"Result of FDG PET\u2010CT Imaging After Immunochemotherapy Induction Is a Powerful and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: an Analysis From the PRIMA Study","volume":"116","author":"Trotman J.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_9_20_1","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"WHO","year":"2001"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2012.09086.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2012.09086.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T03:49:51Z","timestamp":1698724191000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2012.09086.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,13]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1365-2141.2012.09086.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09086.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,13]]},"assertion":[{"value":"2011-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-01-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}